Capricor Therapeutics (NASDAQ: CAPR) reported Q2 EPS of ($0.29), $0.06 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $3.92 million versus the consensus estimate of $3 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.